Results 231 to 240 of about 157,236 (308)

Successful Full‐Term Pregnancy in Clinically Diagnosed Congenital Thrombotic Thrombocytopenic Purpura: A Case Report and Literature Review

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Thrombotic thrombocytopenic purpura (TTP) is a rare, life‐threatening thrombotic microangiopathy resulting from severe ADAMTS13deficiency. Congenital TTP (cTTP, Upshaw–Schulman syndrome) arises from biallelic mutations in the ADAMTS13 gene, leading to lifelong enzyme deficiency, often manifesting in childhood and requiring chronic
Zahra Rahimi, Neda Hashemi, Elham Pishgar, Marziyeh Ghalamkari   +3 more
wiley   +1 more source

Characteristics and posttransplant outcomes of patients with congenital and acquired von Willebrand disease and hemophilia A and with renal transplants. [PDF]

Res Pract Thromb Haemost
Chang IW, Truman M, Yee C, Padrnos L.
europepmc   +1 more source

Bioresorbable Scaffolds for Coronary Arteries: Where Do We Stand Today?

VIEW Medicine, Volume 1, Issue 1, August 2026.
Bioresorbable coronary scaffolds are moving from thick strut pitfalls to thinner, stronger, healing‐oriented designs. Integrating advances in materials, guided implantation with preparation, size, and postdilation steps, and resorption aligned to healing, we synthesize clinical evidence and chart a roadmap toward intelligent, transient platforms ...
Junya Matsuda, Tatsuya Watanabe, Satoshi Yuhara, John M. Kelly, Hirotsugu Kurobe, Toshiharu Shinoka   +5 more
wiley   +1 more source

Type 3 von Willebrand disease in Ethiopia: a comprehensive literature review and report of the first three cases. [PDF]

Thromb J
Arega G, Zewde EB, Said AM, Tesfaye SZ, Tamiru TY, Belisa TK, Ejersa MS, Deress AS.   +7 more
europepmc   +1 more source

Postpartum Acquired Hemophilia A in Two Women With Previously Undiagnosed Carrier Status for von Willebrand Disease Type 2N and Heterozygous p.R854Q Mutation. [PDF]

Haemophilia
Weise M, Klöter T, Keller M, Petros S, Pfrepper C.   +4 more
europepmc   +1 more source

Real-word evidence on healthcare resource use and associated costs in on-demand users of replacement therapies in von Willebrand disease in France: the FORvWARD study. [PDF]

J Comp Eff Res
Polack B, Nerich V, Micallef CM, Trossaërt M, Biron-Andreani C, Bornier N, Chatelanaz C, Favre-Besse F, Beoletto J, Née M, Belhassen M, Lefèvre C, Pouvourville G.   +12 more
europepmc   +1 more source

Sexuality and bleeding in von Willebrand disease. [PDF]

Res Pract Thromb Haemost
van Kwawegen CB, Pastoor H, Eikenboom J, Fijnvandraat K, Ypma P, Heubel-Moenen FCJI, van Galen KPM, Mauser-Bunschoten EP, Meijer K, Schols SEM, Cnossen MH, van der Bom JG, de Meris J, Atiq F, Kruip MJHA, Leebeek FWG, WiN Study Group.   +16 more
europepmc   +1 more source

Bridging the Evidence Gap in von Willebrand Disease: A Call to Action for Equitable, Evidence-Based Care. [PDF]

Haemophilia
Uminski K, James P, Connell N, Khalife R.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

von Willebrand disease

Nature Reviews Disease Primers
von Willebrand disease (VWD) is the most common inherited bleeding disorder. The disorder is characterized by excessive mucocutaneous bleeding. The most common bleeding manifestations of this condition include nosebleeds, bruising, bleeding from minor wounds, menorrhagia or postpartum bleeding in women as well as bleeding after surgery.
O. Seidizadeh, J. Eikenboom, Cécile V. Denis, Veronica H Flood, Paula James, P. Lenting, L. Baronciani, J. S. O’Donnell, D. Lillicrap, F. Peyvandi   +9 more
semanticscholar   +4 more sources